The estimated Net Worth of Hubert C Chen is at least $1.63 Thousand dollars as of 20 May 2021. Hubert Chen owns over 3,289 units of Metacrine stock worth over $1,628 and over the last 10 years Hubert sold MTCR stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Hubert Chen MTCR stock SEC Form 4 insiders trading
Hubert has made over 1 trades of the Metacrine stock since 2021, according to the Form 4 filled with the SEC. Most recently Hubert bought 3,289 units of MTCR stock worth $11,840 on 20 May 2021.
The largest trade Hubert's ever made was buying 3,289 units of Metacrine stock on 20 May 2021 worth over $11,840. On average, Hubert trades about 470 units every 0 days since 2014. As of 20 May 2021 Hubert still owns at least 3,289 units of Metacrine stock.
You can see the complete history of Hubert Chen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Hubert Chen's mailing address?
Hubert's mailing address filed with the SEC is C/O METACRINE, INC., 3985 SORRENTO VALLEY BLVD., SUITE C, SAN DIEGO, CA, 92121.
Insiders trading at Metacrine
Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.
What does Metacrine do?
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
What does Metacrine's logo look like?
Complete history of Hubert Chen stock trades at Pfenex and Metacrine
Metacrine executives and stock owners
Metacrine executives and other stock owners filed with the SEC include:
-
Dr. Preston S. Klassen M.D., M.H.S.,
Pres, CEO & Director -
Dr. Preston S. Klassen,
Pres, CEO & Director -
Patricia M. Millican,
Chief Financial Officer -
Catherine C. Lee,
Consultant -
Michael B. York,
Chief Bus. Officer -
Theresa Lowry,
VP of HR -
Patricia Millican,
Chief Financial Officer -
Andrew Guggenhime,
Director -
Jeffrey David Jonker,
Director -
John G Mc Hutchison,
Director -
Venture Fund Viii, L.P.Arch...,
-
Kristina Burow,
Director -
Preston Klassen,
Director -
Enterprise Associates 16, L...,
-
Trisha Millican,
Chief Financial Officer -
Forest Baskett,
10% owner -
Ali Behbahani,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ronald M Evans,
Director -
Carmen Chang,
10% owner -
Mohamad Makhzoumi,
10% owner -
Amir Nashat,
Director -
Management Co. Vii, L.L.C.P...,
-
Joshua Makower,
10% owner -
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Paul Edward Walker,
10% owner -
Global Strategic Fund, L.P....,
-
Robert J Adelman,
-
Hubert C Chen,
Chief Medical Officer -
Catherine Chai Zon Lee,
EVP, Gen. Counsel & Secretary -
Julia C. Owens,
Director -
Richard A. Heyman,
Director -
Global Strategic Fund, L.P....,
-
Michael York,
Chief Business Officer -
Braden Michael Leonard,
10% owner